Latest National Comprehensive Cancer Network Stories
PITTSBURGH, May 24, 2011 /PRNewswire/ -- D3 Oncology Solutions today announced that it will provide its Via Oncology Pathways for a six-month free trial period to enable cancer programs to align the timing of their investment with a strategy for sharing potential savings with payors and other key stakeholders.
PITTSBURGH, April 7, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFxÂ®, will help further the personalization of cancer treatments.
PITTSBURGH, March 1, 2011 /PRNewswire/ -- D3 Oncology Solutions (D3), formerly D3 Radiation Oncology Solutions, has added Via Oncology Pathways for medical oncology to the company's suite of solutions.
Selected abstract points to efficacy of treatment guidelines and need for improved practices CHICAGO, Feb.
A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals.
Researchers have discovered a method for more precise identification of individuals who should undergo testing for genetic mutations of the tumor suppressor gene PTEN, which associates with a variety of conditions including several types of cancers.
HINSDALE, Ill. and THE WOODLANDS, Texas, Jan.
THE WOODLANDS, Texas and ASHEVILLE, N.C., Jan.
MORRISTOWN, N.J. and THE WOODLANDS, Texas, Nov. 30, 2010 /PRNewswire/ -- Hematology Oncology Associates of Northern New Jersey, P.A.
- A woman chauffeur.
- A woman who operates an automobile.